(Q51356317)

4 April 2018

title

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. (English)

1 reference

4 April 2018

main subject

axitinib

1 reference

ChEBI release 2020-05-28

1 reference

Yazdi K Pithavala

1

1 reference

4 April 2018

Ying Chen

2

1 reference

4 April 2018

Melvin Toh

3

1 reference

4 April 2018

Paulina Selaru

4

1 reference

4 April 2018

Robert R LaBadie

5

1 reference

4 April 2018

May Garrett

6

1 reference

4 April 2018

Brian Hee

7

1 reference

4 April 2018

Janessa Mount

8

1 reference

4 April 2018

Grace Ni

9

1 reference

4 April 2018

Karen J Klamerus

10

1 reference

4 April 2018

Michael A Tortorici

11

1 reference

4 April 2018

publication date

27 May 2012

1 reference

4 April 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

4 April 2018

volume

70

1 reference

4 April 2018

issue

1

1 reference

4 April 2018

page(s)

103-112

1 reference

4 April 2018

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Effects of food on clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1888-9

10.1007/S00280-012-1888-9

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018